SUPN Live signals | Maximize Profits with Getagraph.com

SELL 101392 min ago

@ $27.40

Issued: 14 Feb 2024 @ 09:30

Return: 10.44%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -0.36 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	195 006
Average Volume	391 762
Market Cap	1.66B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0.390 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1 513.00
ATR14	$0.0240 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Bhatt Padmanabh P.	Buy	14 491	Common Stock
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Employee Stock Option (Right to Buy)
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Common Stock
2024-03-20	Bhatt Padmanabh P.	Sell	400	Employee Stock Option (Right to Buy)
2024-03-20	Bhatt Padmanabh P.	Buy	400	Common Stock

INSIDER POWER
38.23
Last 100 transactions
Buy: 802 366 \| Sell: 356 762

Volume Correlation

Long: 0.02 (neutral)

Short: -0.55 (weak negative)

Signal:(44.738) Neutral

Supernus Pharmaceuticals Correlation

10 Most Positive Correlations
FGEN	0.881
CRNC	0.878
IPHA	0.878
CRTO	0.876
ORIC	0.875
TBNK	0.873
MOMO	0.87
VRDN	0.869
RGLD	0.868
DOOO	0.868

10 Most Negative Correlations
PCRX	-0.866
LLNW	-0.859
SFET	-0.848
NBRV	-0.842
MTEX	-0.834
IMTX	-0.831
ZENV	-0.831
SWAV	-0.829
DSPC	-0.827
RIVN	-0.825

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Supernus Pharmaceuticals Correlation - Currency/Commodity

-0.36
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.33
( neutral )

-0.05
( neutral )

-0.15
( neutral )

Supernus Pharmaceuticals Financials

Annual	2023
Revenue:	$607.52M
Gross Profit:	$438.88M (72.24 %)
EPS:	$0.0241

Q4	2023
Revenue:	$164.31M
Gross Profit:	$123.01M (74.86 %)
EPS:	$0.0215

Q3	2023
Revenue:	$153.88M
Gross Profit:	$134.28M (87.26 %)
EPS:	$-0.290

Q2	2023
Revenue:	$135.56M
Gross Profit:	$114.47M (84.44 %)
EPS:	$-0.0152

Financial Reports:

No articles found.

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.